Plus Therapeutics (PSTV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
14 May, 2026Opening remarks and agenda
Meeting called to order at 9:01 A.M. Eastern Time on May 14, 2026, chaired by the President and CEO.
Agenda included consideration of proposals set forth in the proxy statement dated March 31, 2026.
No Q&A session was held; stakeholders were directed to investor relations for questions.
Board and executive committee updates
Proposal to elect six members to the board for one-year terms was presented and approved.
Shareholder proposals
Four proposals were considered: board election, ratification of auditors, advisory vote on executive compensation, and amendment of the 2020 Stock Incentive Plan.
The adjournment proposal was not brought to the floor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Plus Therapeutics
- $15M raise funds pivotal trials, CNSide scale-up, and 2026 commercial expansion.PSTV
Business update9 Jul 2026 - $15M financing and clinical progress support CNSide's 2025 launch and CNS cancer milestones.PSTV
Q4 20248 Jul 2026 - Cerenome rebrands and advances CNS oncology with integrated therapeutics, diagnostics, and AI.PSTV
Investor update1 Jul 2026 - Shelf registration allows flexible securities offerings; Canaccord Genuity LLC is distribution agent.PSTV
Registration filing5 Jun 2026 - At-the-market equity offering of up to $17.35M targets CNS cancer innovation, with dilution risk.PSTV
Registration filing2 Jun 2026 - 186RNL shows safety, efficacy, and immune activation in leptomeningeal metastases.PSTV
2026 AANS Annual Scientific Meeting presentation22 May 2026 - Net loss narrowed, cash and investments rose, and funding remains critical amid clinical and commercial progress.PSTV
Q1 202615 May 2026 - Key votes include director elections, auditor ratification, and executive pay approval.PSTV
Proxy filing31 Mar 2026 - Board seeks approval for director elections, auditor ratification, and expanded equity plan.PSTV
Proxy filing31 Mar 2026